Portal:COVID-19/CoveredPWs
From WikiPathways
(Difference between revisions)
| Line 4: | Line 4: | ||
| SARS-CoV-2 and COVID-19 Pathway|| Collaborative project for curation of biological processes <br/> involved in the COVID-19 disease after SARS-Cov-2 infection. || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved | | SARS-CoV-2 and COVID-19 Pathway|| Collaborative project for curation of biological processes <br/> involved in the COVID-19 disease after SARS-Cov-2 infection. || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved | ||
|- | |- | ||
| - | | Hijack of Ubiquitination by SARS-CoV-2 || || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved | + | | Hijack of Ubiquitination by SARS-CoV-2 || SARS-CoV-2 includes a novel Orf10 that interacts with <br/> multiple members of the Cullin 2 ubiquitin ligase complex. || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved |
|- | |- | ||
| - | | Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | + | | Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || The induction and signaling of type I interferon <br/> with specific SARS-CoV-2 protein and relevant drug. || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress |
|- | |- | ||
| - | | COVID-19, thrombosis and anticoagulation || || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | + | | COVID-19, thrombosis and anticoagulation || A commonly seen phenotype in patients suffering from Corona || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress |
|- | |- | ||
| - | | Activation of NLRP3 Inflammasome by SARS-CoV-2 || || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | + | | Activation of NLRP3 Inflammasome by SARS-CoV-2 || Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress |
|- | |- | ||
| SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | | SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | ||
Revision as of 19:35, 9 September 2020
| Title | Comment | Links WP | Category | Status |
|---|---|---|---|---|
| SARS-CoV-2 and COVID-19 Pathway | Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. | WP4846 | SARS-CoV-2 Pathways | Approved |
| Hijack of Ubiquitination by SARS-CoV-2 | SARS-CoV-2 includes a novel Orf10 that interacts with multiple members of the Cullin 2 ubiquitin ligase complex. | WP4860 | SARS-CoV-2 Pathways | Approved |
| Type I Interferon Induction and Signaling During SARS-CoV-2 Infection | The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. | WP4868 | SARS-CoV-2 Pathways | In Progress |
| COVID-19, thrombosis and anticoagulation | A commonly seen phenotype in patients suffering from Corona | WP4927 | SARS-CoV-2 Pathways | In Progress |
| Activation of NLRP3 Inflammasome by SARS-CoV-2 | Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. | WP4876 | SARS-CoV-2 Pathways | In Progress |
| SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: Molecular mechanisms and potential therapeutic target | WP4883 | SARS-CoV-2 Pathways | In Progress | |
| COVID-19 AOP | WP4891 | SARS-CoV-2 Pathways | In Progress | |
| nsp9/nsp10-mediated SARS-CoV-2 pathogenesis | WP4884 | SARS-CoV-2 Pathways | In Progress | |
| LDLRAD4 pathway in COVID-19 | WP4904 | SARS-CoV-2 Pathways | In Progress | |
| Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 | WP4936 | SARS-CoV-2 Pathways | In Progress | |
| Coronavirus lipid metabolism | WP4853 | Other coronaviruses | In Progress | |
| Host-pathogen interaction of human corona viruses - autophagy | WP4863 | Other coronaviruses | In Progress | |
| Host-pathogen interaction of human corona viruses - apoptosis | WP4864 | Other coronaviruses | In Progress | |
| SARS coronavirus and innate immunity | WP4912 | Other coronaviruses | In Progress | |
| ER stress response in Coronavirus infection | WP4861 | Other coronaviruses | In Progress | |
| Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein | WP4799 | Other coronaviruses | In Progress | |
| Host-pathogen interaction of human corona viruses - MAPK signaling | WP4877 | Other coronaviruses | In Progress | |
| Host-pathogen interaction of human corona viruses - Interferon induction | WP4880 | Other coronaviruses | In Progress | |
| ACE Inhibitor Pathway | WP554 | ACE2 | In Progress | |
| Metabolism of Angiotensinogen to Angiotensins (Reactome) | WP2729 | ACE2 | In Progress |
Pathway categories
The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2).
Contact us
Send questions about WikiPathways to the wikipathways-discuss mailing list.
How to add a pathway to the portal
The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact the administrator.
- See our Help section for New Contributor QuickStart, Editor's Palette Guide and Guidelines for Contributors.
